Information Provided By: 
Fly News Breaks for August 2, 2019
AMED
Aug 2, 2019 | 08:15 EDT
RBC Capital analyst Frank Morgan raised his price target on Amedisys to $150 after its "strong" Q2 beat, with organic growth seen in both segments and margin expansion in home health offsetting the drag from CCM. The analyst lowers his FY20 EPS view to $4.27 from $4.58, modeling a "more conservative" scenario around Patient Driven Groupings Model but keeps his Outperform rating, saying the company still has "strong capital structure and liquidity position" in place for potential M&A.
News For AMED From the Last 2 Days
There are no results for your query AMED
